APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Measles Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174008370430 December 2025208 pages

Choose your research edition.

Industry ResearchLive Attenuated Measles Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Live Attenuated Measles Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live Attenuated Measles Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live Attenuated Measles Vaccine market include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Measles Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Measles Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Measles Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Measles Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Measles Vaccine Segment by Company

GSK

Bavarian Nordic

CSL Limited

Emergent Biosolutions

Medimmune

Sanofi-Pasteur

Serum Institute of India

Beijing Institute of Biological Products Co., Ltd

Pfizer

Lanzhou Institute of Biological Products Co., Ltd

Merck

Novartis

Johnson & Johnson

Shanghai Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Measles Vaccine Segment by Type

Liquid

Powder

Live Attenuated Measles Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Measles Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Live Attenuated Measles Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Live Attenuated Measles Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live Attenuated Measles Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Live Attenuated Measles Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Measles Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Measles Vaccine industry.

Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Live Attenuated Measles Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Live Attenuated Measles Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Measles Vaccine Industry Trends Table 2. Live Attenuated Measles Vaccine Industry Drivers Table 3. Live Attenuated Measles Vaccine Industry Opportunities and Challenges Table 4. Live Attenuated Measles Vaccine Industry Restraints Table 5. Global Live Attenuated Measles Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Measles Vaccine Revenue Share by Company (2021-2026) Table 7. Global Live Attenuated Measles Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Live Attenuated Measles Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Live Attenuated Measles Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Live Attenuated Measles Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Live Attenuated Measles Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Live Attenuated Measles Vaccine Company, Product Type & Application Table 13. Global Live Attenuated Measles Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Liquid Table 18. Significant Companies of Powder Table 19. Global Live Attenuated Measles Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Live Attenuated Measles Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Live Attenuated Measles Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Live Attenuated Measles Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Live Attenuated Measles Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Live Attenuated Measles Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Live Attenuated Measles Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Live Attenuated Measles Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Live Attenuated Measles Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Live Attenuated Measles Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Live Attenuated Measles Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Live Attenuated Measles Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Live Attenuated Measles Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Live Attenuated Measles Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Live Attenuated Measles Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Live Attenuated Measles Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Live Attenuated Measles Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Live Attenuated Measles Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Live Attenuated Measles Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Live Attenuated Measles Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Live Attenuated Measles Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Live Attenuated Measles Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Live Attenuated Measles Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Live Attenuated Measles Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Live Attenuated Measles Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Live Attenuated Measles Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Live Attenuated Measles Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Live Attenuated Measles Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Live Attenuated Measles Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Live Attenuated Measles Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Live Attenuated Measles Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Live Attenuated Measles Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Live Attenuated Measles Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Live Attenuated Measles Vaccine Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. GSK Live Attenuated Measles Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Bavarian Nordic Company Information Table 69. Bavarian Nordic Business Overview Table 70. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio Table 72. Bavarian Nordic Recent Development Table 73. CSL Limited Company Information Table 74. CSL Limited Business Overview Table 75. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CSL Limited Live Attenuated Measles Vaccine Product Portfolio Table 77. CSL Limited Recent Development Table 78. Emergent Biosolutions Company Information Table 79. Emergent Biosolutions Business Overview Table 80. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio Table 82. Emergent Biosolutions Recent Development Table 83. Medimmune Company Information Table 84. Medimmune Business Overview Table 85. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Medimmune Live Attenuated Measles Vaccine Product Portfolio Table 87. Medimmune Recent Development Table 88. Sanofi-Pasteur Company Information Table 89. Sanofi-Pasteur Business Overview Table 90. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio Table 92. Sanofi-Pasteur Recent Development Table 93. Serum Institute of India Company Information Table 94. Serum Institute of India Business Overview Table 95. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio Table 97. Serum Institute of India Recent Development Table 98. Beijing Institute of Biological Products Co., Ltd Company Information Table 99. Beijing Institute of Biological Products Co., Ltd Business Overview Table 100. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 102. Beijing Institute of Biological Products Co., Ltd Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Live Attenuated Measles Vaccine Product Portfolio Table 107. Pfizer Recent Development Table 108. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 109. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 110. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 112. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 113. Merck Company Information Table 114. Merck Business Overview Table 115. Merck Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Merck Live Attenuated Measles Vaccine Product Portfolio Table 117. Merck Recent Development Table 118. Novartis Company Information Table 119. Novartis Business Overview Table 120. Novartis Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Novartis Live Attenuated Measles Vaccine Product Portfolio Table 122. Novartis Recent Development Table 123. Johnson & Johnson Company Information Table 124. Johnson & Johnson Business Overview Table 125. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio Table 127. Johnson & Johnson Recent Development Table 128. Shanghai Institute of Biological Products Co., Ltd Company Information Table 129. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 130. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 132. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 133. Wuhan Institute of Biological Products Co., Ltd Company Information Table 134. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 135. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 137. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 138. Changchun Qijian Biological Products Co., Ltd Company Information Table 139. Changchun Qijian Biological Products Co., Ltd Business Overview Table 140. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 142. Changchun Qijian Biological Products Co., Ltd Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Live Attenuated Measles Vaccine Distributors List Table 146. Live Attenuated Measles Vaccine Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Live Attenuated Measles Vaccine Product Image Figure 2. Global Live Attenuated Measles Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Measles Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Measles Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Live Attenuated Measles Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Liquid Image Figure 10. Powder Image Figure 11. Global Live Attenuated Measles Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Live Attenuated Measles Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Live Attenuated Measles Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Live Attenuated Measles Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Live Attenuated Measles Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Live Attenuated Measles Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Live Attenuated Measles Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Live Attenuated Measles Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Live Attenuated Measles Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Live Attenuated Measles Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Live Attenuated Measles Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Live Attenuated Measles Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Live Attenuated Measles Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Live Attenuated Measles Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Live Attenuated Measles Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Live Attenuated Measles Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Live Attenuated Measles Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Live Attenuated Measles Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Live Attenuated Measles Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Live Attenuated Measles Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Live Attenuated Measles Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Live Attenuated Measles Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Live Attenuated Measles Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions
  • Medimmune
  • Sanofi-Pasteur
  • Serum Institute of India
  • Beijing Institute of Biological Products Co., Ltd
  • Pfizer
  • Lanzhou Institute of Biological Products Co., Ltd
  • Merck
  • Novartis
  • Johnson & Johnson
  • Shanghai Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Measles Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Live Attenuated Measles Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Live Attenuated Measles Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Live Attenuated Measles Vaccine Market Dynamics
  1. 2.1 Live Attenuated Measles Vaccine Industry Trends
  2. 2.2 Live Attenuated Measles Vaccine Industry Drivers
  3. 2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Measles Vaccine Industry Restraints
3 Live Attenuated Measles Vaccine Market by Company
  1. 3.1 Global Live Attenuated Measles Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Live Attenuated Measles Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Live Attenuated Measles Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Live Attenuated Measles Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Live Attenuated Measles Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Live Attenuated Measles Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Live Attenuated Measles Vaccine Company Product Type and Application
  8. 3.8 Global Live Attenuated Measles Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Live Attenuated Measles Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Measles Vaccine Market by Type
  1. 4.1 Live Attenuated Measles Vaccine Type Introduction
  2. 4.1.1 Liquid
  3. 4.1.2 Powder
  4. 4.2 Global Live Attenuated Measles Vaccine Sales Volume by Type
  5. 4.2.1 Global Live Attenuated Measles Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Measles Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Measles Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Measles Vaccine Sales Value by Type
  9. 4.3.1 Global Live Attenuated Measles Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Measles Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Measles Vaccine Sales Value Share by Type (2021-2032)
5 Live Attenuated Measles Vaccine Market by Application
  1. 5.1 Live Attenuated Measles Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Measles Vaccine Sales Volume by Application
  5. 5.2.1 Global Live Attenuated Measles Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Measles Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Measles Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Measles Vaccine Sales Value by Application
  9. 5.3.1 Global Live Attenuated Measles Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Measles Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Measles Vaccine Sales Value Share by Application (2021-2032)
6 Live Attenuated Measles Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Measles Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Live Attenuated Measles Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Live Attenuated Measles Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Live Attenuated Measles Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Live Attenuated Measles Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Live Attenuated Measles Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Live Attenuated Measles Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Live Attenuated Measles Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Live Attenuated Measles Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Live Attenuated Measles Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Live Attenuated Measles Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Live Attenuated Measles Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Live Attenuated Measles Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Live Attenuated Measles Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Live Attenuated Measles Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Live Attenuated Measles Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Live Attenuated Measles Vaccine Sales Value Share by Country, 2025 VS 2032
7 Live Attenuated Measles Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Live Attenuated Measles Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live Attenuated Measles Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Live Attenuated Measles Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Live Attenuated Measles Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Live Attenuated Measles Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Live Attenuated Measles Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Live Attenuated Measles Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Live Attenuated Measles Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Live Attenuated Measles Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Live Attenuated Measles Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Bavarian Nordic
  8. 8.2.1 Bavarian Nordic Company Information
  9. 8.2.2 Bavarian Nordic Business Overview
  10. 8.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
  12. 8.2.5 Bavarian Nordic Recent Developments
  13. 8.3 CSL Limited
  14. 8.3.1 CSL Limited Company Information
  15. 8.3.2 CSL Limited Business Overview
  16. 8.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
  18. 8.3.5 CSL Limited Recent Developments
  19. 8.4 Emergent Biosolutions
  20. 8.4.1 Emergent Biosolutions Company Information
  21. 8.4.2 Emergent Biosolutions Business Overview
  22. 8.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
  24. 8.4.5 Emergent Biosolutions Recent Developments
  25. 8.5 Medimmune
  26. 8.5.1 Medimmune Company Information
  27. 8.5.2 Medimmune Business Overview
  28. 8.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
  30. 8.5.5 Medimmune Recent Developments
  31. 8.6 Sanofi-Pasteur
  32. 8.6.1 Sanofi-Pasteur Company Information
  33. 8.6.2 Sanofi-Pasteur Business Overview
  34. 8.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
  36. 8.6.5 Sanofi-Pasteur Recent Developments
  37. 8.7 Serum Institute of India
  38. 8.7.1 Serum Institute of India Company Information
  39. 8.7.2 Serum Institute of India Business Overview
  40. 8.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Recent Developments
  43. 8.8 Beijing Institute of Biological Products Co., Ltd
  44. 8.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  48. 8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 8.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 8.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 8.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  60. 8.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
  72. 8.12.5 Novartis Recent Developments
  73. 8.13 Johnson & Johnson
  74. 8.13.1 Johnson & Johnson Company Information
  75. 8.13.2 Johnson & Johnson Business Overview
  76. 8.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
  78. 8.13.5 Johnson & Johnson Recent Developments
  79. 8.14 Shanghai Institute of Biological Products Co., Ltd
  80. 8.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  81. 8.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  82. 8.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  84. 8.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  85. 8.15 Wuhan Institute of Biological Products Co., Ltd
  86. 8.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  87. 8.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  88. 8.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  90. 8.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  91. 8.16 Changchun Qijian Biological Products Co., Ltd
  92. 8.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
  93. 8.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  94. 8.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  96. 8.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Measles Vaccine Value Chain Analysis
  2. 9.1.1 Live Attenuated Measles Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Measles Vaccine Sales Mode & Process
  6. 9.2 Live Attenuated Measles Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Measles Vaccine Distributors
  9. 9.2.3 Live Attenuated Measles Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst